Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.

doi:10.1093/jnci/djaa076

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.

Journal of the National Cancer Institute - 4 Jan 2021

Bandini Marco, Ross Jeffrey S, Raggi Daniele, Gallina Andrea, Colecchia Maurizio, Lucianò Roberta, Giannatempo Patrizia, Farè Elena, Pederzoli Filippo, Bianchi Marco, Colombo Renzo, Gandaglia Giorgio, Fossati Nicola, Marandino Laura, Capitanio Umberto, Deho' Federico, Ali Siraj M, Madison Russell, Chung Jon H, Salonia Andrea, Briganti Alberto, Montorsi Francesco, Necchi Andrea

Abstract excerpt

BACKGROUND: In the PURE-01 study (NCT02736266), we aimed to evaluate the ability to predict the pathologic complete response (pT0N0) after pembrolizumab by using clinical and tumor biomarkers. METHODS: In an open-label, single-arm, phase 2 study, 3 courses of 200 mg pembrolizumab preceding radical cystectomy were administered in patients with T2-4aN0M0 muscle-invasive bladder cancer. The analyses included a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Italy

Share to Muscles

Share to Neoadjuvant Therapy

Share to Neoplasm Invasiveness

Share to Tumor Burden

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 32516377
DOI: 10.1093/jnci/djaa076
PMCID: PMC7781448

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.PMID 32516377Read ↗

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.Semantic proximity Read ↗

Prediction of pan-solid tumor pembrolizumab benefit by integrating tumor mutation and gene expression profilingSemantic proximity Read ↗

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.Semantic proximity Read ↗

Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.Semantic proximity Read ↗

Complete Response To Tislelizumab In A Muscle-Invasive Urothelial Carcinoma After Surgery Associated With Tumor Mutational Burden High: A Case ReportSemantic proximity Read ↗

Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.Semantic proximity Read ↗

Resistance to Platinum-Based Chemotherapy in Muscle-Invasive Bladder Cancer: Genetic and Immune Determinants and Implications for Treatment Sequencing — A Case SeriesSemantic proximity Read ↗

A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report.Semantic proximity Read ↗

Real-World Outcomes of Second-Line Pembrolizumab in Urothelial Carcinoma: A Multicenter Analysis from the Campania Oncological Network (ROC)Semantic proximity Read ↗

Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent mannerSemantic proximity Read ↗

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.Semantic proximity Read ↗

A Spatial Comparison of Molecular Features Associated with Resistance to Pembrolizumab in BCG Unresponsive Bladder CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.